Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
XLO Stock Forecast 2026-2027
$7.70
Current Price
$50.63M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to XLO Price Targets
+159.7%
To High Target of $20.00
+159.7%
To Median Target of $20.00
+159.7%
To Low Target of $20.00
XLO Price Momentum
-9.0%
1 Week Change
-1.4%
1 Month Change
-21.4%
1 Year Change
-14.1%
Year-to-Date Change
-39.6%
From 52W High of $12.74
+19.0%
From 52W Low of $6.47
📊 TOP ANALYST CALLS
Did XLO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Xilio is one of their latest high-conviction picks.
Latest XLO Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, XLO has a bullish consensus with a median price target of $20.00 (ranging from $20.00 to $20.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $7.70, the median forecast implies a 159.7% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XLO Analyst Ratings
1
Buy
0
Hold
0
Sell
XLO Price Target Range
Low
$20.00
Average
$20.00
High
$20.00
Current: $7.70
Latest XLO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XLO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 6, 2025 | Leerink Partners | Daina Graybosch | Outperform | Initiates | $2.00 |
| Nov 8, 2024 | Raymond James | Outperform | Maintains | $N/A | |
| May 30, 2023 | Chardan Capital | Buy | Reiterates | $N/A | |
| May 11, 2023 | Chardan Capital | Buy | Reiterates | $N/A | |
| Jan 27, 2023 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Dec 21, 2022 | Chardan Capital | Buy | Initiates | $N/A | |
| Nov 10, 2022 | Raymond James | Outperform | Maintains | $N/A | |
| Aug 10, 2022 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Jan 10, 2022 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Nov 16, 2021 | Raymond James | Outperform | Initiates | $N/A | |
| Nov 16, 2021 | Cowen & Co. | Outperform | Initiates | $N/A | |
| Nov 16, 2021 | Morgan Stanley | Overweight | Initiates | $N/A |
Xilio Therapeutics, Inc. (XLO) Competitors
The following stocks are similar to Xilio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Xilio Therapeutics, Inc. (XLO) Financial Data
Xilio Therapeutics, Inc. has a market capitalization of $50.63M with a P/E ratio of -1.8x. The company generates $53.48M in trailing twelve-month revenue with a -58.5% profit margin.
Revenue growth is +331.7% quarter-over-quarter, while maintaining an operating margin of -111.6% and return on equity of -75.2%.
Valuation Metrics
Market Cap
$50.63M
Enterprise Value
$-93,977,608
P/E Ratio
-1.8x
PEG Ratio
0.0x
Price/Sales
0.9x
Growth & Margins
Revenue Growth (YoY)
+331.7%
Gross Margin
N/A
Operating Margin
-111.6%
Net Margin
-58.5%
EPS Growth
+331.7%
Financial Health
Cash/Price Ratio
+326.3%
Current Ratio
3.6x
Debt/Equity
9.2x
ROE
-75.2%
ROA
-19.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Xilio Therapeutics, Inc. (XLO) Business Model
About Xilio Therapeutics, Inc.
What They Do
Develops tumor-activated immuno-oncology therapies.
Business Model
Xilio Therapeutics operates as a clinical-stage biotechnology company that focuses on developing innovative immuno-oncology therapies. The company generates revenue through strategic collaborations with major pharmaceutical companies, such as AbbVie, which help fund its research and development efforts in exchange for access to its proprietary technologies and therapies.
Additional Information
Xilio's pipeline includes several promising candidates like vilastobart and efarindodekin alfa, aimed at treating advanced solid tumors and metastatic colorectal cancer. The company’s masked immunotherapy platform is designed to enhance immune responses specifically within the tumor environment, aiming to reduce systemic side effects often associated with cancer treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
76
CEO
Dr. Rene Russo BCPS, Pharm.D.
Country
United States
IPO Year
2021
Website
xiliotx.comXilio Therapeutics, Inc. (XLO) Latest News & Analysis
Latest News
Quick Summary
Oncology innovation is boosting growth in cancer-focused biotech and pharma stocks, driven by advancements in AI, immunotherapy, and targeted therapies.
Why It Matters
Accelerating oncology innovation suggests strong growth potential for biotech and pharma stocks, signaling investment opportunities in a booming sector driven by advanced treatments.
Source: Zacks Investment Research
Market Sentiment:
Positive
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
25 days ago
Quick Summary
XTX501, a bispecific PD-1/ masked IL-2 therapy, is on schedule for an IND submission in mid-2026 and Phase 1 trial initiation in H2 2026.
Why It Matters
The timeline for XTX501's IND submission and Phase 1 initiation indicates progress in drug development, potentially impacting future revenue and market position for the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Xilio Therapeutics (XLO) reported a quarterly loss of $0.58 per share, better than the estimated loss of $0.66, compared to a loss of $2.52 per share a year prior.
Why It Matters
Xilio's smaller-than-expected loss signals improved financial performance, potentially boosting investor confidence and affecting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Xilio Therapeutics granted 1,982 non-qualified stock options to a new employee as of May 1, 2026, under its 2022 Inducement Stock Incentive Plan.
Why It Matters
Granting stock options can indicate company growth and attract talent, signaling confidence in future performance, which may positively influence investor sentiment and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Xilio Therapeutics appointed Cheryl R. Blanchard, Ph.D. to its board of directors, while Christina Rossi has stepped down, effective April 15, 2026.
Why It Matters
Leadership changes can signal strategic shifts or new directions for a company, impacting investor confidence and stock performance in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
XTX601 showed tumor-selective activation and strong anti-tumor effects in several preclinical models, indicating potential for cancer treatment development.
Why It Matters
XTX601's targeted anti-tumor activity in preclinical models suggests potential for significant advancements in cancer treatment, potentially impacting market valuations and investment opportunities in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About XLO Stock
What is Xilio Therapeutics, Inc.'s (XLO) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Xilio Therapeutics, Inc. (XLO) has a median price target of $20.00. The highest price target is $20.00 and the lowest is $20.00.
Is XLO stock a good investment in 2026?
According to current analyst ratings, XLO has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XLO stock?
Wall Street analysts predict XLO stock could reach $20.00 in the next 12 months. This represents a 159.7% increase from the current price of $7.70. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Xilio Therapeutics, Inc.'s business model?
Xilio Therapeutics operates as a clinical-stage biotechnology company that focuses on developing innovative immuno-oncology therapies. The company generates revenue through strategic collaborations with major pharmaceutical companies, such as AbbVie, which help fund its research and development efforts in exchange for access to its proprietary technologies and therapies.
What is the highest forecasted price for XLO Xilio Therapeutics, Inc.?
The highest price target for XLO is $20.00 from at , which represents a 159.7% increase from the current price of $7.70.
What is the lowest forecasted price for XLO Xilio Therapeutics, Inc.?
The lowest price target for XLO is $20.00 from at , which represents a 159.7% increase from the current price of $7.70.
What is the overall XLO consensus from analysts for Xilio Therapeutics, Inc.?
The overall analyst consensus for XLO is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are XLO stock price projections?
Stock price projections, including those for Xilio Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 3:28 AM UTC